Acute treatment with TrkB agonist LM22A-4 confers neuroprotection and preserves myelin integrity in a mouse model of pediatric traumatic brain injury
Jessica L. Fletcher, Larissa K. Dill, Rhiannon J. Wood, Sharon Wang, Kate Robertson, Simon S. Murray, Akram Zamani, Bridgette D. Semple
This study shows that acute treatment with TrkB agonist LM22A-4 after pediatric TBI reduces tissue damage and preserves myelin integrity, with some behavioral improvements.
Experimental Neurology · Feb 18, 2021Peer-reviewedNeuroscience